5-<2-Chlorphenyl>-1-methyl-3H-1,4-benzodiazepin-2(1H)-on | 18100-68-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 5-<2-Chlorphenyl>-1-methyl-3H-1,4-benzodiazepin-2(1H)-on
• 英文别名: 5-(2-chloro-phenyl)-1-methyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one；5-(2-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2(1H)-one；5-(2-chlorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one
• CAS: 18100-68-0
• 化学式: C₁₆H₁₃ClN₂O
• 分子量: 284.745
• InChiKey: BPWINVKSLHXFPN-UHFFFAOYSA-N

物化性质

• 沸点：
  480.9±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES
  申请人：Cook James M.

  公开号：US20100261711A1

  公开（公告）日：2010-10-14

  In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of seizures. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of seizures with reduced sedative and ataxic side effects.

  在优选实施方式中，本发明提供了用于抑制、缓解和预防癫痫发作的治疗方法和药物组合物。本发明的优选实施方式进一步涉及使用苯二氮䓬类衍生物的治疗方法和药物组合物，该类衍生物在减少镇静和共济失调副作用的同时提供了抑制、缓解和预防癫痫发作的效果。
• STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS
  申请人：Cook James M.

  公开号：US20100004226A1

  公开（公告）日：2010-01-07

  The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-IV, VI-XI, XV-XVIII and XX-XXI and a pharmaceutically-acceptable carrier.

  本发明提供了立体特异性苯二氮平衍生物、其盐和前药的组合物及使用方法，用于治疗焦虑或惊厥性疾病，在人类酗酒者中具有减少酒精渴望的副作用，以及同时减少镇静、催眠、肌肉松弛和共济失调的副作用。本发明进一步提供了用于治疗需要该类治疗的焦虑和惊厥性疾病患者的药物组合物，包括具有化学结构的化合物、前药或盐Formula I-IV、VI-XI、XV-XVIII和XX-XXI中的任意一个，并且是药学可接受的载体。
• ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS
  申请人：Cook M. James

  公开号：US20080108605A1

  公开（公告）日：2008-05-08

  Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

  本发明揭示了口服活性苯二氮平衍生物及其盐。这些化合物及其盐具有抗焦虑和抗癫痫活性，同时减少镇静/催眠/肌肉松弛/共济失调等副作用。
• ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS
  申请人：Cook James M.

  公开号：US20100130481A1

  公开（公告）日：2010-05-27

  Methods of using orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anticonvulsant and anxiolytic activity with reduced sedative, hypnotic, muscle relaxant, or ataxic effects.

  本发明揭示了使用口服活性苯二氮平衍生物及其盐的方法。这些化合物及其盐具有抗惊厥和抗焦虑活性，同时减少了镇静、催眠、肌肉松弛或共济失调等副作用。
• USE OF PERIPHERAL-TYPE BENZODIAZEPINE SITES FOR TREATMENT OF CNS TRAUMA OR DISEASE
  申请人：COCENSYS, INC.

  公开号：EP0616532A1

  公开（公告）日：1994-09-28